NASDAQ:SRDX Surmodics (SRDX) Stock Price, News & Analysis $41.44 -0.11 (-0.26%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$41.31▼$41.7750-Day Range$34.22▼$42.2452-Week Range$25.17▼$42.44Volume206,665 shsAverage Volume444,518 shsMarket Capitalization$590.93 millionP/E Ratio43.62Dividend YieldN/APrice Target$50.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Surmodics alerts: Email Address Surmodics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside20.7% Upside$50.00 Price TargetShort InterestHealthy5.12% of Float Sold ShortDividend StrengthN/ASustainability-2.52Upright™ Environmental ScoreNews Sentiment0.75Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to $0.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.97 out of 5 starsMedical Sector212th out of 936 stocksSurgical & Medical Instruments Industry29th out of 101 stocks 2.0 Analyst's Opinion Consensus RatingSurmodics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageSurmodics has only been the subject of 4 research reports in the past 90 days.Read more about Surmodics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.12% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surmodics has recently decreased by 12.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSurmodics does not currently pay a dividend.Dividend GrowthSurmodics does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSurmodics has received a 38.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic antigens", " Coatings for drug delivery devices", and "Medical equipment engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Surmodics is -2.52. Previous Next 3.2 News and Social Media Coverage News SentimentSurmodics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Surmodics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for SRDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Surmodics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surmodics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.90% of the stock of Surmodics is held by insiders.Percentage Held by Institutions96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Surmodics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Surmodics are expected to grow in the coming year, from ($0.51) to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surmodics is 43.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.05.Price to Earnings Ratio vs. SectorThe P/E ratio of Surmodics is 43.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 156.27.Price to Book Value per Share RatioSurmodics has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Surmodics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Surmodics Stock (NASDAQ:SRDX)Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.Read More SRDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRDX Stock News HeadlinesJuly 26 at 1:27 AM | americanbankingnews.comSurmodics (NASDAQ:SRDX) Research Coverage Started at StockNews.comJuly 20, 2024 | americanbankingnews.comSurmodics (NASDAQ:SRDX) Now Covered by StockNews.comJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.July 8, 2024 | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. – SRDXJuly 3, 2024 | prnewswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDXJune 10, 2024 | businesswire.comSurmodics Awarded Thrombectomy Products Agreement with Premier, Inc.May 29, 2024 | prnewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.May 29, 2024 | marketwatch.comSurmodics Shares Up in Premarket on $627M Go-Private Deal With GTCRJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.May 29, 2024 | msn.comHeico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On WednesdayMay 29, 2024 | markets.businessinsider.comGTCR To Acquire Surmodics - Quick FactsMay 29, 2024 | tmcnet.comSRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to ShareholdersMay 29, 2024 | msn.comSurmodics jumps 18% on acquisition by GTCRMay 29, 2024 | benzinga.comWhy Is Medical Coating Specialist Surmodics Trading Higher On Wednesday?May 29, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Surmodics, Inc. has obtained a Fair Price for its Public ShareholdersMay 29, 2024 | businesswire.comSurmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 MillionMay 21, 2024 | finance.yahoo.comSurmodics, Inc.'s (NASDAQ:SRDX) Intrinsic Value Is Potentially 96% Above Its Share PriceMay 4, 2024 | finance.yahoo.comSurmodics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextSee More Headlines Receive SRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/27/2024Next Earnings (Estimated)8/07/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:SRDX CUSIP86887310 CIK924717 Webwww.surmodics.com Phone(952) 500-7000Fax952-500-7001Employees376Year Founded1979Price Target and Rating Average Stock Price Target$50.00 High Stock Price Target$71.00 Low Stock Price Target$43.00 Potential Upside/Downside+20.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.95 Trailing P/E Ratio43.62 Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,540,000.00 Net Margins9.44% Pretax Margin12.10% Return on Equity13.30% Return on Assets8.63% Debt Debt-to-Equity Ratio0.24 Current Ratio4.39 Quick Ratio3.59 Sales & Book Value Annual Sales$142.96 million Price / Sales4.13 Cash Flow$0.78 per share Price / Cash Flow53.32 Book Value$8.48 per share Price / Book4.89Miscellaneous Outstanding Shares14,260,000Free Float12,991,000Market Cap$590.93 million OptionableOptionable Beta1.18 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Gary R. Maharaj (Age 61)CEO, President & Director Comp: $1.33MMr. Timothy J. Arens (Age 57)Senior VP of Finance & Information Technology and CFO Comp: $645.3kMr. Gordon S. Weber (Age 61)Senior VP of Legal, General Counsel & Secretary Comp: $602.84kMr. Charles W. Olson (Age 60)Senior VP & President of Medical Device Coatings Comp: $618.47kMs. Teryl L. W. Sides (Age 54)Senior VP & President of Vascular Interventions Comp: $744.38kMr. John D. Manders (Age 43)Corporate Controller, VP of Finance & Principal Accounting Officer Mr. Joseph J. Stich (Age 59)Senior VP of Human Resources & President of In Vitro Diagnostics Comp: $570.92kMore ExecutivesKey CompetitorsAnika TherapeuticsNASDAQ:ANIKIntersect ENTNASDAQ:XENTAntares PharmaNASDAQ:ATRSCytosorbentsNASDAQ:CTSOVapothermNYSE:VAPOView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 8,220 shares on 7/26/2024Ownership: 0.411%Bailard Inc.Bought 6,123 shares on 7/26/2024Ownership: 0.043%Nisa Investment Advisors LLCBought 67,010 shares on 7/20/2024Ownership: 0.480%Salem Investment Counselors Inc.Sold 350 shares on 7/11/2024Ownership: 0.846%California State Teachers Retirement SystemSold 882 shares on 5/16/2024Ownership: 0.010%View All Institutional Transactions SRDX Stock Analysis - Frequently Asked Questions How have SRDX shares performed this year? Surmodics' stock was trading at $36.35 at the beginning of the year. Since then, SRDX stock has increased by 14.0% and is now trading at $41.44. View the best growth stocks for 2024 here. How were Surmodics' earnings last quarter? Surmodics, Inc. (NASDAQ:SRDX) announced its quarterly earnings results on Wednesday, May, 1st. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.43. The firm had revenue of $31.96 million for the quarter, compared to analyst estimates of $28.79 million. Surmodics had a net margin of 9.44% and a trailing twelve-month return on equity of 13.30%. What is Gary Maharaj's approval rating as Surmodics' CEO? 8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees. Who are Surmodics' major shareholders? Top institutional shareholders of Surmodics include Salem Investment Counselors Inc. (0.85%), Nisa Investment Advisors LLC (0.48%), Bank of New York Mellon Corp (0.41%) and Bailard Inc. (0.04%). Insiders that own company stock include Gary R Maharaj, Charles W Olson, David Dantzker, Ronald B Sr Kalich Sr, Jose H Bedoya, John D Manders and Joseph J Stich. View institutional ownership trends. How do I buy shares of Surmodics? Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Surmodics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM) and uniQure (QURE). This page (NASDAQ:SRDX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surmodics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRDX Stock Alerts